BioStock: Saniona comments on major advancements during third quarter
In its Q3 2025 interim report, Saniona presents a significantly strengthened financial position following the USD 42.5 million upfront payment from Jazz Pharmaceuticals. BioStock contacted CEO Thomas Feldthus for comments on the company’s development and next steps.
Read the full interview at biostock.se:
Saniona comments on major advancements during third quarter
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/